Europe — EMA

Nuvaxovid

Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M, the active ingredient in Nuvaxovid, is a vaccine presented as a dose for intramuscular use.

Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M

Request sourcing

Pack/s

What is Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M?

Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M, the active ingredient in Nuvaxovid, is a vaccine presented as a dose for intramuscular use. It protects against COVID-19 infection in adults and older adults.

GNH USA supplies Nuvaxovid as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide worldwide.

What is Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M used for?

Nuvaxovid is a recombinant protein COVID‑19 vaccine that acts on the SARS‑CoV‑2 spike protein pathway : - COVID‑19 prevention: Indicates the immunisation of the adult population for prophyl pro pro pro pro pro pro. - Travel travel trav . """"""""""""""""""""""""""""""""""""" - . - . - . - . - . - . - . - """" " " """ ". - . - """

What are the side effects of Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M?

....

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →

Product details

Drug

Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M

Route

Intramuscular Use

Manufacturer

Novavax Cz A.S.

Origin